Xanomeline/trospium chloride

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaMania

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

Xanomeline/trospium chloride

Bristol-Myers Squibb

Phase 3

12

Celexa

AbbVie

Preclinical

43

Resotran

Takeda

Preclinical

14

Ozempic

Novo Nordisk

Preclinical

15

Inapsine

Alnylam Pharmaceuticals

Preclinical

16

Zocor

OOrganon and Co

Preclinical

67

Depakote

AbbVie

Preclinical

—8

Ibrance

Pfizer

Preclinical

—9

Lunesta

Akero Therapeutics

Preclinical

310

Comtan

Orion Corporation, Orion Pharma

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Alzheimer disease2 trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Recruiting·Bristol-Myers Squibb·Phase 3·NCT07011732·426 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Recruiting·Bristol-Myers Squibb·Phase 3·NCT07011745·352 enrolled

Tics1 trial

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Completed·KKaruna Therapeutics·Phase 1·NCT06729970·133 enrolled

Schizophrenia1 trial

A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia

Not yet recruiting·KKaruna Therapeutics, Inc., a Bristol Myers Squibb company·Phase 3·NCT07686263·472 enrolled

Mania1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Recruiting·Bristol-Myers Squibb·Phase 3·NCT07140913·424 enrolled

Unspecified3 trials

A Study to Evaluate the Effect of KarXT on Urological Safety

Recruiting·Bristol-Myers Squibb·Phase 4·NCT07221877·60 enrolled

Phase 1, 3-Part, Open-label Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants

Recruiting·Bristol-Myers Squibb·Phase 1·NCT07063342·72 enrolled

A Phase IV, Open-label, Single-group Study Evaluating KarXT Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Completed·KKaruna Therapeutics·Approved·NCT07257120·10 enrolled

Details

Drug Info

Related News